Repositioning Candidates

Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3

Search for:

     Insulin resistance
10 records.
Candidate ID Source ID Source Type Compound Type Candidate Name Inclusion Criteria
R0391 DB01067 approved; investigational small molecule Glipizide Therapeutic strategy associated Details
R0690 DB05064 investigational small molecule INCB13739 Therapeutic strategy associated Details
R0875 DB05804 investigational small molecule Prasterone sulfate Therapeutic strategy associated Details
R1042 DB06536 investigational small molecule Tesaglitazar Target associated Details
R1164 DB08834 experimental; investigational small molecule Tauroursodeoxycholic acid Indication associated Details
R1254 DB09230 investigational small molecule Azelnidipine Therapeutic strategy associated Details
R1410 DB11827 approved; investigational small molecule Ertugliflozin Target associated Details
R1485 DB13174 experimental small molecule Rhein Therapeutic strategy associated Details
R1486 DB13178 approved; investigational; withdrawn small molecule Inositol Therapeutic strategy associated Details
R1541 DB14751 approved biotech Mecasermin rinfabate Indication associated Details